Routes of
administration Oral CAS Number 442201-24-3 UNII TR0QT6QSUL Molar mass 522.586 g/mol | ATC code none ChemSpider 8047110 KEGG D10055 | |
 | ||
Remogliflozin etabonate (INN/USAN) is a proposed drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin is being developed by Avolynt, Inc.
Contents
Clinical trials
Remogliflozin etabonate (RE) was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels. Remogliflozin etabonate has been studied at doses up to 1000 mg. A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.
Method of action
Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.